Video

Dr. Khushman on Best Practices in the Management of GI Cancers

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.

Moh’d Khushman, MD, associate professor, Kirklin Clinic of the University of Alabama (UAB) Hospital, UAB Medicine, discusses best practices in the management of gastrointestinal (GI) cancers.

Molecular profiling is critical for all patients with advanced pancreatic cancer because the results could inform optimal treatment selection in this population, Khushman explains.

In hepatocellular carcinoma (HCC), eligible patients should receive frontline atezolizumab (Tecentriq) plus bevacizumab (Avastin), which is the standard of care, Khushman says.

Finally, patients with gastric/gastroesophageal junction or esophageal adenocarcinoma should receive chemoimmunotherapy in the frontline setting, particularly if they have a PD-L1 combined positive score of at least 5, Khushman concludes.

Related Videos
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Elias Jabbour, MD